279 related articles for article (PubMed ID: 17075126)
1. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of gene expression-based classification for neuroblastoma.
Oberthuer A; Hero B; Berthold F; Juraeva D; Faldum A; Kahlert Y; Asgharzadeh S; Seeger R; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Vermeulen J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Weber A; Christiansen H; Grundy RG; Schardt K; Schwab M; Eils R; Warnat P; Kaderali L; Simon T; Decarolis B; Theissen J; Westermann F; Brors B; Fischer M
J Clin Oncol; 2010 Jul; 28(21):3506-15. PubMed ID: 20567016
[TBL] [Abstract][Full Text] [Related]
3. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
[TBL] [Abstract][Full Text] [Related]
6. Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T; Liu J
Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
[TBL] [Abstract][Full Text] [Related]
7. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
8. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease.
Oberthuer A; Warnat P; Kahlert Y; Westermann F; Spitz R; Brors B; Hero B; Eils R; Schwab M; Berthold F; Fischer M
Cancer Lett; 2007 Jun; 250(2):250-67. PubMed ID: 17126996
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
[TBL] [Abstract][Full Text] [Related]
10. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
11. Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction.
Schramm A; Mierswa I; Kaderali L; Morik K; Eggert A; Schulte JH
Cancer Lett; 2009 Sep; 282(1):55-62. PubMed ID: 19349112
[TBL] [Abstract][Full Text] [Related]
12. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data.
Gui J; Li H
Bioinformatics; 2005 Jul; 21(13):3001-8. PubMed ID: 15814556
[TBL] [Abstract][Full Text] [Related]
13. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.
Lee ES; Son DS; Kim SH; Lee J; Jo J; Han J; Kim H; Lee HJ; Choi HY; Jung Y; Park M; Lim YS; Kim K; Shim Y; Kim BC; Lee K; Huh N; Ko C; Park K; Lee JW; Choi YS; Kim J
Clin Cancer Res; 2008 Nov; 14(22):7397-404. PubMed ID: 19010856
[TBL] [Abstract][Full Text] [Related]
14. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer.
Lin YH; Friederichs J; Black MA; Mages J; Rosenberg R; Guilford PJ; Phillips V; Thompson-Fawcett M; Kasabov N; Toro T; Merrie AE; van Rij A; Yoon HS; McCall JL; Siewert JR; Holzmann B; Reeve AE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):498-507. PubMed ID: 17255271
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.
van Gils W; Lodder EM; Mensink HW; Kiliç E; Naus NC; Brüggenwirth HT; van Ijcken W; Paridaens D; Luyten GP; de Klein A
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4254-62. PubMed ID: 18552379
[TBL] [Abstract][Full Text] [Related]
16. Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia.
Bresolin S; Zecca M; Flotho C; Trentin L; Zangrando A; Sainati L; Stary J; de Moerloose B; Hasle H; Niemeyer CM; Te Kronnie G; Locatelli F; Basso G
J Clin Oncol; 2010 Apr; 28(11):1919-27. PubMed ID: 20231685
[TBL] [Abstract][Full Text] [Related]
17. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
18. Gene expression signature predicts recurrence in lung adenocarcinoma.
Larsen JE; Pavey SJ; Passmore LH; Bowman RV; Hayward NK; Fong KM
Clin Cancer Res; 2007 May; 13(10):2946-54. PubMed ID: 17504995
[TBL] [Abstract][Full Text] [Related]
19. Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
Reid JF; Lusa L; De Cecco L; Coradini D; Veneroni S; Daidone MG; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2005 Jun; 97(12):927-30. PubMed ID: 15956654
[TBL] [Abstract][Full Text] [Related]
20. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy.
Diallo-Danebrock R; Ting E; Gluz O; Herr A; Mohrmann S; Geddert H; Rody A; Schaefer KL; Baldus SE; Hartmann A; Wild PJ; Burson M; Gabbert HE; Nitz U; Poremba C
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):488-97. PubMed ID: 17255270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
